2014
Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results
Holkova B, Kmieciak M, Bose P, Ma S, Kimball A, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Singh A, Dean A, Conine S, Sankala H, Roberts J, Shea T, Grant S. Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results. Blood 2014, 124: 3050. DOI: 10.1182/blood.v124.21.3050.3050.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaPeripheral T-cell lymphomaDose level 2aIndolent B-cell lymphomaT-cell lymphomaSmall lymphocytic lymphomaRefractory CLL/small lymphocytic lymphomaB-cell lymphomaCLL/small lymphocytic lymphomaDose level 1Adverse eventsLymphocytic lymphomaChronic lymphocytic leukemia/small lymphocytic lymphomaGrade 2 adverse eventsGrade 3 adverse eventsLevel 2bLevel 2aGrade 3 fatigueGrade 3 vomitingReversible grade 2Cytokine release syndromeGrade 4 neutropeniaECOG performance scorePhase 1 studySoft tissue infections
2012
Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma
Holkova B, Shea T, Bose P, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts J, Grant S. Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood 2012, 120: 1794. DOI: 10.1182/blood.v120.21.1794.1794.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaIndolent B-cell lymphomaDose level 2aSoft tissue infectionsCLL/SLLT-cell lymphomaAdverse eventsSmall lymphocytic lymphomaB-cell lymphomaTissue infectionsLymphocytic lymphomaGrade 3Grade 2 cytokine release syndromeChronic lymphocytic leukemia/small lymphocytic lymphomaRefractory CLL/SLLLevel 2bCTCAE version 4DLT-evaluable patientsReversible grade 2Cytokine release syndromeDose level 1Grade 4 neutropeniaNausea/vomitingSerious adverse eventsECOG performance score
2003
RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 665-672. PMID: 14529770, DOI: 10.1016/s0360-3016(03)00718-1.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellChemotherapy, AdjuvantCisplatinCombined Modality TherapyConfidence IntervalsCystectomyFemaleHumansMaleMethotrexateMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingRadiation-Sensitizing AgentsRadiotherapyRemission InductionUrinary Bladder NeoplasmsVinblastineConceptsGrade 3 toxicityAdjuvant chemotherapyInduction therapyOverall survivalResidual diseaseAdditional adjuvant chemotherapyBladder-sparing treatmentCycles of methotrexateGrade 4 hydronephrosisGrade 4 neutropeniaSelective bladder conservationEvidence of diseaseClinical T stagePositive cytologic findingsAggressive transurethral resectionRTOG 97Surgery specimenKarnofsky scoreLocoregional controlLocoregional failureCombination cisplatinMost patientsPathologic reviewProtocol treatmentVinblastine chemotherapy